Savara Inc. (SVRA) Stock Score, Valuation & Financial Research

Savara Inc. is in the Healthcare sector and Biotechnology industry. It is reviewed using Wall Street Score's company-strength, valuation, growth and financial-health framework. A complete Wall Street Score is not currently available.

Quick answer for SVRA

Savara Inc. does not currently have a complete Wall Street Score. The stored market price is USD 4.65. These figures are a research snapshot, not a buy or sell recommendation.

What Savara Inc. does

Savara Inc. is a biopharmaceutical firm in the clinical development phase, specializing in therapies for uncommon respiratory conditions. Their primary investigational drug, molgramostim, is an inhaled form of granulocyte-macrophage colony-stimulating factor (GM-CSF). This compound is currently undergoing Phase III trials to address autoimmune pulmonary alveolar proteinosis. The company's main operations are situated in Austin, Texas.

Company business and revenue

Research reporting period: 2025-12-31. A research update is not a new financial filing.

How the company makes money

Savara Inc. is a clinical-stage biopharmaceutical company that focuses on the development and commercialization of therapies for rare respiratory diseases. The company has not yet generated any product revenue and currently relies on raising capital to fund its research, development, and clinical trial activities.

Products and services

  • The company's primary product candidate is MOLBREEVI (molgramostim), an inhaled granulocyte-macrophage colony-stimulating factor (GM-CSF) for the treatment of autoimmune pulmonary alveolar proteinosis (aPAP).

Brands and product families

  • MOLBREEVI — Inhaled molgramostim product candidate for autoimmune pulmonary alveolar proteinosis. Source

Customer types

Patients with rare respiratory diseases.

Suppliers, materials and equipment

  • Contract Manufacturing Organizations (CMOs) — The company relies on third-party contract manufacturing organizations for the production of its clinical trial materials. Source
  • Contract Research Organizations (CROs) — The company utilizes third-party contract research organizations to manage and conduct its clinical trials. Source

Business strengths to evaluate

  • Focused pipeline on rare respiratory diseases with orphan drug designations Source

Business risks and research considerations

  • History of operating losses and no product revenue Source
  • Regulatory risks including potential for FDA refusal to file or rejection of BLA Source
  • Dependence on third-party manufacturers and clinical research organizations Source

Sources: Company research source

Company research refreshed 2026-10-12. This is saved research, not a live check of company relationships. Check the reporting period and source disclosures. Financial figures and scores follow their separate update schedules.

SVRA financial snapshot

Statement amounts: USD. Quote amounts: USD. No exchange-rate conversion is performed in this snapshot. Market-capitalization currency is not supplied by this projection.

Wall Street Score:
Not currently available
Stored price:
USD 4.65
Market capitalization:
952.91M (currency not supplied)
Revenue:
USD 0.00
Net income:
USD -139.31M
Free cash flow:
USD -101.06M
Cash:
USD 41.8M
Total debt:
USD 30.11M
EPS:
USD -0.58

What stands out

  • Free cash flow is USD -101.06M, negative for the stored period.
  • The balance sheet shows USD 41.8M of cash versus USD 30.11M of total debt, an excess of cash over debt on these two reported measures.
  • The current research record carries a fundamental change risk warning, which should be reviewed alongside the score.

Company-specific financial comparisons

The following are calculated from saved company data, not forecasts or statements about future performance. Differences in reporting dates or units can make a ratio misleading; verify the original filings.

  • Cash exceeds debt by USD 11.69M using the stored balance-sheet values. This does not include other obligations or restricted cash.

Questions worth answering for SVRA

Use these questions to check the stored figures against the latest company filings. They identify issues to investigate; they are not findings about management's plans or future results.

  • How long can SVRA fund negative free cash flow using its current cash position before it may need more debt or new shares?
  • Does SVRA's balance between cash and debt leave enough flexibility if business conditions weaken?
  • What specifically needs to improve for SVRA to reach sustainable profitability?
  • What does the current fundamental change risk warning mean for the reliability or interpretation of SVRA's score?

What the numbers mean

A complete valuation score is not currently available, so valuation should be checked using the available earnings, cash-flow and price data.

A complete financial score is not currently available, so investors should review cash, debt, earnings and cash flow directly.

A strong company and an attractive stock price are not always the same thing. Revenue, earnings, free cash flow, debt, management quality, competitive advantage and valuation should be considered together. Wall Street Score organizes these inputs into a consistent research framework so investors can identify what deserves deeper review.

Data freshness: Financial data last refreshed 2026-10-01.

Research-input completeness: 73% of the scoring inputs required for this public page are currently available.

How to research SVRA

Start by understanding how the company makes money. Then compare revenue and earnings trends, cash generation, debt, liquidity and valuation. Review the company's latest filings and earnings reports before acting on any score or model estimate.

Learn how to analyze a stock · Read the Wall Street Score methodology · Browse other stocks

Data may change as company filings and market prices update. Educational research only; not a buy or sell recommendation.